China Resources Boya Bio-pharmaceutical GroupLtd Dividend
Dividend criteria checks 4/6
China Resources Boya Bio-pharmaceutical GroupLtd is a dividend paying company with a current yield of 0.88% that is well covered by earnings.
Key information
0.9%
Dividend yield
69%
Payout ratio
Industry average yield | 1.2% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Earnings per share | CN¥0.43 |
Dividend yield forecast in 3Y | 0.4% |
Recent dividend updates
Recent updates
China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Is Increasing Its Dividend To CN¥0.30
Apr 26Is China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Using Too Much Debt?
Apr 22China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Conservative Accounting Might Explain Soft Earnings
Apr 01What Does The Future Hold For China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)? These Analysts Have Been Cutting Their Estimates
Mar 31Stability and Growth of Payments
Fetching dividends data
Stable Dividend: 300294's dividend payments have been volatile in the past 10 years.
Growing Dividend: 300294's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
China Resources Boya Bio-pharmaceutical GroupLtd Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (300294) | 0.9% |
Market Bottom 25% (CN) | 0.6% |
Market Top 25% (CN) | 2.3% |
Industry Average (Biotechs) | 1.2% |
Analyst forecast in 3 Years (300294) | 0.4% |
Notable Dividend: 300294's dividend (0.88%) is higher than the bottom 25% of dividend payers in the CN market (0.65%).
High Dividend: 300294's dividend (0.88%) is low compared to the top 25% of dividend payers in the CN market (2.25%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (69.4%), 300294's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (33.1%), 300294's dividend payments are well covered by cash flows.